Azenta, Inc. 8-K

What Happened
Azenta, Inc. (Nasdaq: AZTA) filed an 8‑K reporting that on April 6, 2026 Ginger Zhou stepped down as President of the company’s Multiomics business and will support Azenta as a consultant through November 2026. Effective April 6, 2026 the company appointed William “Trey” E. Martin III as President, Multiomics; he reports to CEO John Marotta. Azenta furnished a press release about the leadership transition on April 7, 2026.

Key Details

• Ginger Zhou’s departure was not due to any disagreement with the company. She entered a separation agreement and a consulting services agreement providing an initial consulting fee of $103,500, payable in seven equal monthly installments and prorated if term <7 months.
• William “Trey” E. Martin III: base salary $540,000; eligible for 2026 annual incentive with a target bonus = 80% of base salary (prorated for portion of year employed).
• Equity & one‑time awards (subject to Board approval): initial long‑term equity target ≈ $1.7M (50% performance RSUs / 50% time‑based RSUs, prorated for 2026) and a one‑time performance equity award ≈ $500,000 (performance RSUs over a one‑year period).
• Severance: If terminated without cause (or resigns for good reason) unrelated to a change in control, Martin is eligible for 12 months salary continuation and continued medical/dental/vision coverage (subject to execution of a release). If termination occurs within one year after a change in control, he would receive a lump sum equal to base salary + target bonus, a prorated bonus for the year, and one year of benefit continuation (subject to release).
• Azenta also amended offer letters for executives Lawrence Lin, Ephraim Starr and Olga Pirogova to clarify/change severance and change‑in‑control benefits; amendments provide for lump‑sum change‑in‑control severance (base salary + target bonus), prorated bonus for year of termination, and one year of continued health benefits. Pirogova’s amendment also provides 12 months salary continuation (and benefits during continuation) if terminated without cause or for good reason unrelated to a change in control.

Why It Matters
This 8‑K discloses an executive leadership change in Azenta’s Multiomics segment, including the hiring terms and potential compensation and severance obligations that could affect near‑term cash compensation and long‑term equity dilution. Investors should note the costs disclosed (consulting fee, salary, target bonuses, and potential equity grants) and the strengthened change‑in‑control/severance protections for multiple senior executives, which could be relevant when assessing executive incentives and future cash or share‑based expense.